Honors & Awards


  • Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship (Parent F31), NIH NIDCR (2015-2018)

Professional Education


  • Doctor of Philosophy, Rice University, Bioengineering (2019)
  • Master of Bioengineering, Rice University, Bioengineering (2012)
  • Bachelor of Science, Loyola Marymount University, Mechanical Engineering (2009)

Stanford Advisors


All Publications


  • Cabozantinib Reverses Renal Cell Carcinoma-Mediated Osteoblast Inhibition in Three-Dimensional Co-culture In Vitro and Reduces Bone Osteolysis In Vivo. Molecular cancer therapeutics Pan, T., Martinez, M., Hubka, K. M., Song, J. H., Lin, S., Yu, G., Lee, Y., Gallick, G. E., Tu, S., Harrington, D. A., Farach-Carson, M. C., Lin, S., Satcher, R. L. 2020

    Abstract

    Renal cell carcinoma (RCC) bone metastases (RCCBM) are typically osteolytic. We previously showed that BIGH3 (beta Ig-h3/TGFbI), secreted by 786-O RCC, plays a role in osteolytic bone lesion in RCCBM through inhibition of osteoblast (OSB) differentiation. To study this interaction, we employed three-dimensional (3D) hydrogels to co-culture bone-derived 786-O RCC cells (Bo-786) with MC3T3-E1 pre-osteoblasts (OSB). Culturing pre-osteoblasts in the 3D hydrogels preserved their ability to differentiate into mature OSB; however, this process was decreased when pre-osteoblasts were co-cultured with Bo-786 cells. Knockdown of BIGH3 in Bo-786 cells recovered OSB differentiation. Further, treatment with bone morphogenetic protein 4 (BMP4), which stimulates osteoblast differentiation, or cabozantinib (CBZ), which inhibits VEGFR1 and MET tyrosine kinase activities, also increased OSB differentiation in the co-culture. CBZ also inhibited pre-osteoclast RAW264.7 cell differentiation. Using RCCBM mouse models, we showed that CBZ inhibited Bo-786 tumor growth in bone. CBZ treatment also increased bone volume and OSB number, and decreased osteoclast number and blood vessel density. When tested in SN12PM6 RCC cells that have been transduced to overexpress BIGH3, CBZ also inhibited SN12PM6 tumor growth in bone. These observations suggest that enhancing OSB differentiation could be one of the therapeutic strategies for treating RCCBM that exhibit OSB inhibition characteristics, and that this 3D co-culture system is an effective tool for screening osteoanabolic agents for further in vivo studies.

    View details for DOI 10.1158/1535-7163.MCT-19-0174

    View details for PubMedID 32220969

  • Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels ACTA BIOMATERIALIA Hubka, K. M., Carson, D. D., Harrington, D. A., Farach-Carson, M. C. 2019; 97: 385–98

    Abstract

    Growth factor gradients orchestrate many biological processes including organogenesis, wound healing, cancer invasion, and metastasis. Heparin-binding growth factor (HBGF) gradients are established in living systems by proteoglycans including the extracellular matrix heparan sulfate proteoglycan, perlecan/HSPG2. Three potential HBGF-binding glycosaminoglycan attachment sites occur in N-terminal domain I of perlecan's five domains. Our overarching goal was to form stable, biomimetic non-covalently bound HBGF gradients surrounding cells encapsulated in hyaluronate-based hydrogels by first establishing perlecan domain I (PlnD1) gradients. A versatile multichannel gradient maker device (MGMD) was designed and 3D printed, then used to create desired gradients of microparticles in hydrogels. Next, we used the device to covalently incorporate gradients of PEGylated PlnD1 in hydrogels with high-low-high or high-medium-low concentrations across the hydrogel width. Fluorescently-labeled fibroblast growth factor-2 was delivered to hydrogels in phosphate-buffered saline and allowed to electrostatically bind to the covalently pre-incorporated PlnD1, producing stable non-covalent HBGF gradients. To test cell viability after flow through the MGMD, delicate primary human salivary stem/progenitor cells were encapsulated in gradient hydrogels where they showed high viability and continued to grow. Next, to test migratory behavior in response to HBGF gradients, two cell types, preosteoblastic MC3T3-E1 cell line and breast cancer cell line MDA-MB-231 were encapsulated in or adjacent to PlnD1-modified hydrogels. Both cell lines migrated toward HBGFs bound to PlnD1. We conclude that establishing covalently-bound PlnD1 gradients in hydrogels provides a new means to establish physiologically-relevant gradients of HBGFs that are useful for a variety of applications in tissue engineering and cancer biology. STATEMENT OF SIGNIFICANCE: Gradients of heparin binding growth factors (HBGFs) direct cell behavior in living systems. HBGFs bind electrostatically to gradients of HS proteoglycans in the extracellular matrix creating HBGF gradients. We recreated HBGF gradients in physiological hyaluronate-based hydrogels using a 3D-printed multichannel gradient maker device (MGMD) that created gradients of HS proteoglycan-derived perlecan/HSPG2 domain I. We demonstrated the ability of a variety of cells, including primary salivary stem/progenitor cells, pre-osteoblastic cells and an invasive breast cancer cell line, to be co-encapsulated in gradient hydrogels by flowing them together through the MGMD. The versatile device and the ability to create HBGF gradients in hydrogels for a variety of applications is innovative and of broad utility in both cancer biology and tissue engineering applications.

    View details for DOI 10.1016/j.actbio.2019.07.040

    View details for Web of Science ID 000495470300028

    View details for PubMedID 31351252

    View details for PubMedCentralID PMC6801032

  • Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome JOURNAL OF CELLULAR BIOCHEMISTRY Martinez, J. R., Grindel, B. J., Hubka, K. M., Dodge, G. R., Farach-Carson, M. C. 2019; 120 (2): 2138–50

    Abstract

    Perlecan/heparan sulfate proteoglycan 2 (HSPG2), a large HSPG, is indispensable for the development of musculoskeletal tissues, where it is deposited within the pericellular matrix (PCM) surrounding chondrocytes and disappears nearly completely at the chondro-osseous junction (COJ) of developing long bones. Destruction of perlecan at the COJ converts an avascular cartilage compartment into one that permits blood vessel infiltration and osteogenesis. Mutations in perlecan are associated with chondrodysplasia with widespread musculoskeletal and joint defects. This study elucidated novel signaling roles of perlecan core protein in endochondral bone formation and chondrocyte behavior. Perlecan subdomains were tested for chondrogenic properties in ATDC5 cells, a model for early chondrogenesis. A region within domain IV of perlecan (HSPG2 IV-3) was found to promote rapid prechondrocyte clustering. Introduction of the mutation (R3452Q) associated with the human skeletal disorder Schwartz-Jampel syndrome limited HSPG2 IV-3-induced clustering. HSPG2 IV-3 activity was enhanced when thermally unfolded, likely because of increased exposure of the active motif(s). HSPG2 IV-3-induced clustering was accompanied by the deactivation of key components of the focal adhesion complex, FAK and Src, with increased messenger RNA (mRNA) levels of precartilage condensation markers Sox9 and N-cadherin ( Cdh2), and cartilage PCM components collagen II ( Col2a1) and aggrecan ( Acan). HSPG2 IV-3 reduced signaling through the ERK pathway, where loss of ERK1/2 phosphorylation coincided with reduced FoxM1 protein levels and increased mRNA levels cyclin-dependent kinase inhibitor 1C (Cdkn1c) and activating transcription factor 3 ( Atf3), reducing cell proliferation. These findings point to a critical role for perlecan domain IV in cartilage development through triggering chondrocyte condensation.

    View details for DOI 10.1002/jcb.27521

    View details for Web of Science ID 000458822400103

    View details for PubMedID 30203597

    View details for PubMedCentralID PMC6411452

  • Dissociative and Nondissociative Models for Culture of Human Eccrine Glands for Toxicology Testing and Tissue Engineering Applications Applied In Vitro Toxicology Hubka, K. M., Wu, D., Harrington, D. A., Langer, J. C., Pocard, T., Jammayrac, O., Farach-Carson, M. C., Pradhan-Bhatt, S. 2015; 1 (3): 187-197

    View details for DOI 10.1089/aivt.2015.0013

  • Enhancing Chondrogenic Phenotype for Cartilage Tissue Engineering: Monoculture and Coculture of Articular Chondrocytes and Mesenchymal Stem Cells TISSUE ENGINEERING PART B-REVIEWS Hubka, K. M., Dahlin, R. L., Meretoja, V. V., Kasper, F., Mikos, A. G. 2014; 20 (6): 641–54

    Abstract

    Articular cartilage exhibits an inherently low rate of regeneration. Consequently, damage to articular cartilage often requires surgical intervention. However, existing treatments generally result in the formation of fibrocartilage tissue, which is inferior to native articular cartilage. As a result, cartilage engineering strategies seek to repair or replace damaged cartilage with an engineered tissue that restores full functionality to the impaired joint. These strategies often involve the use of chondrocytes, yet in vitro expansion and culture can lead to undesirable changes in chondrocyte phenotype. This review focuses on the use of articular chondrocytes and mesenchymal stem cells (MSCs) in either monoculture or coculture for the enhancement of chondrogenesis. Coculture strategies increasingly outperform their monoculture counterparts with regard to chondrogenesis and present unique opportunities to attain chondrocyte phenotype stability in vitro. Methods to prevent chondrocyte dedifferentiation and promote chondrocyte redifferentiation as well as to promote the chondrogenic differentiation of MSCs while preventing MSC hypertrophy are discussed.

    View details for DOI 10.1089/ten.teb.2014.0034

    View details for Web of Science ID 000345205200007

    View details for PubMedID 24834484

    View details for PubMedCentralID PMC4241977

  • Human cell-conditioned media produced under embryonic-like conditions result in improved healing time after laser resurfacing. Aesthetic plastic surgery Zimber, M. P., Mansbridge, J. N., Taylor, M., Stockton, T., Hubka, M., Baumgartner, M., Rheins, L., Hubka, K., Brandt, E. N., Kellar, R., Naughton, G. K. 2012; 36 (2): 431–37

    Abstract

    Laser resurfacing procedures are continuing to grow in popularity as patients select less invasive procedures for rejuvenation of photo-damaged and aging skin. However, although physicians have begun exploring options to aid in postlaser healing, currently available treatments have little clinical evidence to support their use for wounded skin.When grown under conditions of very low oxygen and suspension, a simulation of the embryonic environment, neonatal cells have been found to produce proteins and growth factors in types and quantities similar to those of fetal cells. The human cell-conditioned media (hCCM) produced by the cells was extracted and formulated into a gel to evaluate its efficacy in the healing of postlaser wounds.A split-face clinical evaluation of the material was performed, with 42 subjects undergoing combination ablative and nonablative laser procedures. Three concentrations of the hCCM were tested (× 0.1, × 1.0, × 10.0), and a dose-response trend was seen in the blinded physician evaluation, particularly in the assessment of crusting. In addition, transepidermal water loss readings showed a significant difference (p ≤ 0.05), indicating a more rapid return to normal skin barrier function with the active treatment. Histopathologic evaluation of subject biopsies showed reduced inflammation and a more normal epidermal appearance in the active treatment sites.The results of this clinical evaluation support the use of the soluble hCCM produced under embryonic-like conditions to accelerate wound healing after laser resurfacing procedures. The utility of the × 10 concentration appears to promote more rapid, scarless wound healing after resurfacing procedures and more normal skin recovery.

    View details for DOI 10.1007/s00266-011-9787-8

    View details for PubMedID 21735336

  • Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. Journal of drugs in dermatology : JDD Zimber, M. P., Ziering, C., Zeigler, F., Hubka, M., Mansbridge, J. N., Baumgartner, M., Hubka, K., Kellar, R., Perez-Meza, D., Sadick, N., Naughton, G. K. 2011; 10 (11): 1308–12

    Abstract

    Research has shown the importance of follistatin, Wnt 7a, and wound healing growth factors on the stimulation of bulge cells and inter-follicular stem cells to induce hair growth. We have studied the effects of a bioengineered, non-recombinant, human cell-derived formulation, termed Hair Stimulating Complex (HSC), containing these factors to assess its hair growth activity in male pattern baldness. HSC showed in vitro Wnt activity and contained follistatin, KGF, and VEGF. The clinical study was a double-blind, placebo-controlled, randomized single site trial and was designed to evaluate safety of the HSC product and assess efficacy in stimulating hair growth. All 26 subjects tolerated the single, intradermal injection of HSC procedures well, and no signs of an adverse reaction were reported. Histopathological evaluation of the treatment site biopsies taken at 22 and 52 weeks post-treatment revealed no abnormal morphology, hamartomas, or other pathological responses. Trichoscan image analysis of HSC-treated sites at 12 and 52 weeks showed significant improvements in hair growth over the placebo. At the initial 12-week evaluation period, HSC-treated sites demonstrated an increase in hair shaft thickness (6.3%±2.5% vs. -0.63%±2.1%; P=0.046), thickness density (12.8%±4.5% vs. -0.2%±2.9%; P=0.028), and terminal hair density (20.6±4.9% vs. 4.4±4.9%; P=0.029). At one year, a statistically significant increase in total hair count (P=0.032) continued to be seen. These results demonstrate that a single intradermal administration of HSC improved hair growth in subjects with androgenetic alopecia and is a clinical substantiation of previous preclinical research with Wnts, follistatin, and other growth factors associated with wound healing and regeneration.

    View details for PubMedID 22052313